Xyrem Risk Management Plan Should Limit Drug's Use To Cataplexy - Cmte.

Orphan Medical's Xyrem risk management program should limit physician use of the gamma hydroxy butyrate product to treatment of cataplexy, FDA's Peripheral & Central Nervous System Drugs Advisory Committee said at its June 6 meeting.